iPSCs: A Minireview from Bench to Bed, including Organoids and the CRISPR System.
iPSCs: A Minireview from Bench to Bed, including Organoids and the CRISPR System.
复制标题
DOI：
10.1155/2016/5934782
复制
发表时间：
2016
影响因子：
4.3
通讯作者：
Pereyra-Bonnet F
中科院分区：
文献类型：
--
作者：
Orqueda AJ;Giménez CA;Pereyra-Bonnet F
当多利羊出生时，第一次对成年哺乳动物基因组的探索穿越回到过去，并产生了一个全新的动物。十年后，重编程过程成为通过四种转录因子的过表达产生诱导多能干细胞（iPSCs）的确定方法。多能干细胞能够产生几乎所有类型的细胞和组织，包括一个全新的动物。基于患者来源细胞的重编程策略应该使基于细胞治疗的临床应用的发展更加直接。在这里，我们分析了iPSCs从实验到实验的现状、机遇和挑战，包括类器官和CRISPR系统。
When Dolly the sheep was born, the first probe into an adult mammalian genome traveling back in time and generating a whole new animal appeared. Ten years later, the reprogramming process became a defined method of producing induced pluripotent stem cells (iPSCs) through the overexpression of four transcription factors. iPSCs are capable of originating virtually all types of cells and tissues, including a whole new animal. The reprogramming strategies based on patient-derived cells should make the development of clinical applications of cell based therapy much more straightforward. Here, we analyze the current state, opportunities, and challenges of iPSCs from bench to bed, including organoids and the CRISPR system.